Equities

SANION

SE0005794617

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:22:31 2024-04-29 am EDT			5-day change	1st Jan Change
1.84 ^SEK	-0.97%		+2.22%	-54.11%

08:08am	Digital Value in 2023 increases revenues by 20 percent; up profit	AN
Mar. 01	Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	MT

BioStock: Saniona's CEO: "financing will bring SAN711 towards proof of concept"

January 23, 2024 at 02:46 am EST

Saniona recently unveiled two new clinical development candidates, expanding its repertoire in ion channel modulation for epilepsy and other neurological disorders. Beyond epilepsy, Saniona manages four clinical programmes, aimed at collaboration opportunities. To propel these assets and potentially forge strategic partnerships, Saniona is carrying out a 140 million SEK rights issue. BioStock talked to Saniona's CEO Thomas Feldthus to learn more.

Read the interview Thomas Feldthus with at biostock.se:

Saniona's CEO: "financing will bring SAN711 towards proof of concept" - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/saniona/r/biostock--saniona-s-ceo---financing-will-bring-san711-towards-proof-of-concept-,c3913471

Latest news about SANA AB

Digital Value in 2023 increases revenues by 20 percent; up profit	02:08am	AN
Sana Biotechnology Shares Rise as Q4 Non-GAAP Net Loss Narrows	Mar. 01	MT
Sector Update: Health Care Stocks Edge Higher Premarket Friday	Mar. 01	MT
Sana Biotechnology Q4 Non-GAAP Net Loss Narrows; Cash, Cash Equivalents Decline	Feb. 29	MT
Saniona AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Saniona AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Israeli missile attack hits high-security district in Syrian capital	Feb. 21	RE
Saniona AB Announces Preliminary and Unaudited Revenue Results for the Fourth Quarter and Full Year 2023	Jan. 16	CI
Saniona Announces the Selection of Its Proprietary GABAA A5 Negative Allosteric Modulator Lead Compound, San2465	Jan. 02	CI
Saniona AB Strengthens Epilepsy Pipeline with Selection of SAN2355 as Clinical Candidate	Dec. 27	CI
Saniona Extends Schizophrenia Treatment Research Collaboration with Boehringer Ingelheim	Dec. 18	MT
Saniona and Boehringer Ingelheim Extend Research Term with Up to Two Years	Dec. 18	CI
Saniona AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 30	CI
Saniona AB Announces Composition of Nomination Committee	Nov. 29	CI
Saniona Promotes Kv7 Epilepsy Compound to Candidate Selection Phase	Nov. 21	CI
Saniona Announces Positive Preclinical Data on Saniona's SAN711 in Epilepsy Presented at SfN	23-10-27	CI
Saniona AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-31	CI
Saniona and Formue Nord Fokus A/S Agreed to Change the Terms of the Loan Agreement of June 30, 2021	23-08-14	CI
Saniona, AstronauTx Partner on Study of Alzheimer's, Neurodegenerative Conditions	23-07-18	MT
Saniona Enters into Collaboration Agreement with Astronautx in Alzheimer's Disease	23-07-17	CI
Saniona AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-25	CI
Saniona AB Auditor Raises 'Going Concern' Doubt	23-04-27	CI
Saniona AB Announces Composition of Nomination Committee	23-04-25	CI
Saniona AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-23	CI
Saniona AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-23	CI

Chart SANA AB

Duration

Period

More charts

Company Profile

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Sector

Biotechnology & Medical Research

Calendar

2024-05-22 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SANA AB	-54.11%	18.73M
VERTEX PHARMACEUTICALS INCORPORATED	-2.63%	102B
REGENERON PHARMACEUTICALS, INC.	+1.62%	96.29B
ARGENX SE	+1.46%	22.18B
BIONTECH SE	-16.67%	21.2B
GENMAB A/S	-8.58%	18.31B
WUXI APPTEC CO., LTD.	-38.74%	17.38B
BEIGENE, LTD.	-13.21%	16.36B
NEUROCRINE BIOSCIENCES, INC.	+5.41%	13.97B
SAREPTA THERAPEUTICS, INC.	+33.57%	12.17B

Bio Therapeutic Drugs